Carl Zeiss Meditec AG
Carl Zeiss Meditec AG (CZMWY) Financial Performance & Income Statement Overview
View comprehensive annual and quarterly summaries for Carl Zeiss Meditec AG (CZMWY), featuring income statements, balance sheets, and cash flow data.
Carl Zeiss Meditec AG (CZMWY) Income Statement & Financial Overview
Explore comprehensive income reports for Carl Zeiss Meditec AG CZMWY, broken down by year and quarter.
| Metric | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 |
|---|---|---|---|---|
| Revenue | $560.02M | $490.50M | $579.63M | $539.34M |
| Cost of Revenue | $258.28M | $238.40M | $289.50M | $245.87M |
| Gross Profit | $301.73M | $252.10M | $290.13M | $293.47M |
| Gross Profit Ratio | $0.54 | $0.51 | $0.50 | $0.54 |
| R&D Expenses | $75.59M | $77.50M | $84.69M | $84.29M |
| SG&A Expenses | $153.87M | $148.70M | $173.51M | $154.81M |
| Operating Expenses | $230.55M | $224.10M | $290.13M | $239.08M |
| Total Costs & Expenses | $488.84M | $462.50M | $579.63M | $484.67M |
| Interest Income | $3.59M | $1.70M | $4.17M | $2.05M |
| Interest Expense | $7.006M | $6.90M | -$32.58M | $8.06M |
| Depreciation & Amortization | $0.00 | $9.41M | $0.00 | $5.41M |
| EBITDA | $72.39M | $37.41M | $78.89M | $60.11M |
| EBITDA Ratio | $0.13 | $0.08 | $0.14 | $0.11 |
| Operating Income | $71.18M | $25.90M | $126.75M | $54.39M |
| Operating Income Ratio | $0.13 | $0.05 | $0.22 | $0.10 |
| Other Income/Expenses (Net) | -$5.80M | -$5.80M | -$57.28M | -$5.07M |
| Income Before Tax | $65.38M | $20.10M | $69.47M | $49.32M |
| Income Before Tax Ratio | $0.12 | $0.04 | $0.12 | $0.09 |
| Income Tax Expense | $19.75M | $5.20M | $6.61M | $15.90M |
| Net Income | $45.33M | $15.70M | $60.73M | $34.13M |
| Net Income Ratio | $0.08 | $0.03 | $0.10 | $0.06 |
| EPS | $0.52 | $0.18 | $0.70 | $0.38 |
| Diluted EPS | $0.52 | $0.18 | $0.70 | $0.38 |
| Weighted Avg Shares Outstanding | $87.17M | $87.22M | $87.22M | $89.74M |
| Weighted Avg Shares Outstanding (Diluted) | $87.17M | $87.22M | $87.22M | $89.74M |
Over the last four quarters, Carl Zeiss Meditec AG's revenue moved from $539.34M in Q3 2024 to $560.02M in Q2 2025. Operating income in Q2 2025 was $71.18M, with a strong operating margin of 13%. Despite fluctuations in R&D and SG&A expenses, EBITDA for Carl Zeiss Meditec AG remained robust at $72.39M, reflecting operational efficiency. Net income rose to $45.33M, with an EPS of $0.52. Disciplined expense management helped sustain profitability, highlighting solid overall financial performance.
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan